DIPHTHERIA VACCINE MARKET ANALYSIS

Market News

Global Diphtheria Vaccine Market: Key Developments

According to an research article published in Frontiers Media S.A., a scientific journal, in October 2021, the study suggest that individuals with registered diphtheria or tetanus vaccinations are less likely to develop severe COVID-19 than people who had only received other vaccinations such as polio, COVID-19, and others.

On December 13, 2022, BIONET-ASIA, a vaccine manufacturing company, announced that they entered into a partnership with Pharmaniaga Berhad, a Malaysian pharmaceutical company to development of a 6-in-1 Hexavalent Vaccine. The vaccine will provide Malaysian health care providers with option to immunize children against six childhood diseases, such as diphtheria (DT), tetanus (TT), pertussis (aP), poliomyelitis (IPV), Haemophilus influenzae type b (Hib), and hepatitis B (Hep-B).

In October 2020, BIONET-ASIA, a vaccine manufacturing company announced that they have completed the Phase-II clinical trials of Tetanus, Diphtheria, Pertussis (In children, Prevention) in Thailand.

In June 2022, GSK plc, a global pharmaceutical company announced that they have invested more than US$ 1.2 Billion to accelerate research and development (R&D) dedicated to develop vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and diphtheria.